Latest Inhibikase Therapeutics Inc. Stories
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001.
ATLANTA, May 17, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc. (Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO ) Dr.
- a meat pie that is usually eaten at Christmas in Quebec